The FDA clinical hold covers two Phase 3 studies for nexiguran ziclumeran, or nex-z, an experimental gene-editing therapy for transthyretin amyloidosis. Nex-z uses the CRISPR gene-editing technology to inactivate the gene that codes for the protein driving this rare disease.
The FDA clinical hold covers two Phase 3 studies for nexiguran ziclumeran, or nex-z, an experimental gene-editing therapy for transthyretin amyloidosis. Nex-z uses the CRISPR gene-editing technology to inactivate the gene that codes for the protein driving this rare disease.
Across the nation, state-based health insurance exchanges are searching for ways to better serve their communities while making enrollment easier, more personal, and more accessible for everyone.
Eli Lilly's LillyDirect platform is partnering with Walmart to let patients pick up prescriptions for its GLP-1 drug Zepbound at Walmart pharmacies, expanding access beyond home delivery.
October has seen a slew of executive hires, exits and layoffs across the healthcare industry. For instance, Eli Lilly, CommonSpirit Health and HLM Venture Partners welcomed new executives. There were also layoffs at organizations including Genentech and Jefferson Health.
We must work together across the care continuum to establish both local and network-trusted identity data management capabilities that can unify patient data across fragmented data silos at both the database layer and the front-end digital and physical access layer.
It's not the flashiest technologies or rapid-speed AI breakthroughs that can do it. It's the technologies laser-focused on the unglamorous but all-consuming coordination problems that suck up medical staff's time, stress them out, and compromise patient care.
[Sponsored] The 2025 Benefits Sentiment Index is based on a survey of 120 benefit consultants to self-insured employers and is sponsored by Quantum Health.
No comments